Exemestane shows high tumor response rate in first-line treatment of advanced breast cancer

September 19, 2003

BRUSSELS, BELGIUM (September 19, 2003) - A study published in the September 2003 issue of Annals of Oncology (vol. 14, issue 9) indicated that exemestane demonstrates a high response rate for first-line treatment of advanced breast cancer in postmenopausal women. Response rate is a measurement of how effective the treatments are in shrinking the tumor.

In this phase II clinical study, 122 patients were randomized to either exemestane (25 mg/day) or tamoxifen (20 mg/day). The results indicate that exemestane was well-tolerated. Women treated with exemestane experienced the following grade 2/3 side-effects compared with those treated with tamoxifen: dyspnea (10 % vs. 8 %), edema or swelling (2 % vs. 11 %), grade 2/3 fatigue (13 % vs. 13 %), hot flashes (3 % vs. 14 %) and bone pain (10 % vs. 15 %). No patients were withdrawn from treatment due to toxicity. Moreover, patients treated with exemestane had three times the response rate (complete plus partial responses) in shrinking tumors (41 % vs. 17 %) relative to tamoxifen-treated patients.

"Although a formal statistical comparison between the two study arms is not allowed in the setting of this phase II clinical trial, the results were found very promising," said Robert J. Paridaens, M.D., Ph.D., professor and head of the medical oncology clinic, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium, and lead investigator for the EORTC Breast Group. "The results lead to the European Organization for Research and Treatment of Cancer (EORTC), the organization that conducted the clinical trial, decision to extend the study in a phase III trial, for which the accrual of 342 patients was recently completed. The final results with statistical comparison of efficacy of both arms (exemestane versus tamoxifen) will be available by end of this year."

Exemestane currently is indicated for the treatment of advanced breast cancer in postmenopausal women whose tumors have stopped responding to tamoxifen. It is the first and only oral drug in a class of aromatase inactivators. Its unique mechanism of action works by selectively targeting and irreversibly binding to the aromatase enzyme. This enzyme is required to produce estrogen in the breast. Since some breast cancer cells need estrogen to survive, once exemestane binds to an enzyme, the enzyme cannot produce estrogen again.

This mechanistic feature, coupled with other clinical trial results to date, prompted the EORTC to conduct this Phase II study. Based on the results, the EORTC has expanded the trial into a Phase III trial of identical design. The efficacy of exemestane in the adjuvant treatment of breast cancer is being examined in worldwide clinical trials involving more than 7,000 patients. In addition, its potential in the prevention of breast cancer is under evaluation.

Exemestane is marketed by Pfizer under the brand name AROMASIN® (exemestane tablets).
About the EORTC
The European Organization for Research and Treatment of Cancer (EORTC), created in 1962, is an international research organization registered under Belgian law. It promotes, conducts and coordinates multi-disciplinary cancer research in 32 countries and represents a unique network of more than 2,500 scientists and clinical investigators organized in 30 groups and 4 task forces, in about 300 cancer centers and clinics. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the development of new drugs and other innovative approaches, and to test effective therapeutic strategies, using drugs, which are already commercially available, or surgery and radiotherapy. In this way, the EORTC facilitates the passage of experimental discoveries into state-of-the-art treatment. Such international cooperation between major European centers minimizes the delay between the discovery of new anti-cancer agents and their therapeutic benefit for patients with cancer.

For more information about the EORTC's research activities, please have a look at our website: http://www.eortc.be

Edelman Public Relations

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.